Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
JCR Can Strike Global Licensing Deal for Lysosomal Therapies at Least by March-End: Chief
JCR Pharmaceuticals believes it can conclude a global licensing deal for its lysosomal storage disease treatments “at least before the end of this fiscal year” through March 2021, Chairman and President Shin Ashida said at an earnings briefing on November…
To read the full story
Related Article
- JCR Chief Delays Global Licensing Timeline for Lysosomal Storage Disorder Therapies
May 20, 2020
- JCR Aims to File Sakigake-Designated Hunter Syndrome Drug in September
May 19, 2020
- JCR Closes ArmaGen Buyout, Gaining IP Rights on Blood-Brain Barrier-Penetrating Technology
April 21, 2020
- JCR Acquiring ArmaGen to Expedite Drug Development for Lysosomal Diseases
March 27, 2020
- JCR to License Lysosome Storage Disease Treatment to Global Player by March 2020: Chairman
May 20, 2019
BUSINESS
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…